Literature DB >> 28450205

Nucleic acid combinations: A new frontier for cancer treatment.

Remant Bahadur K C1, Bindu Thapa2, Juliana Valencia-Serna3, Hamidreza Montezari Aliabadi4, Hasan Uludağ5.   

Abstract

The emerging molecular understanding of cancer cell behavior is leading to increasing possibilities to control unchecked cell growth and metastasis. On the other hand, development of multifunctional drug carriers at the 'nano'-scale is providing exciting new therapeutic strategies in clinical management of cancer beyond the conventional cytotoxic drugs. A new frontier in this regard is the combinational use of complementary agents based on nucleic acids to overcome the limitations of conventional therapy. The existence of tightly-integrated cross-talk through multiple signaling and effector pathways have been appreciated for some time, and the plasticity of such a network to overcome one-dimensional intervention is stimulating development of combinational therapy. The objective of this review is to underline the cutting edge technologies and opportunities employed in combination cancer therapy using nucleic acids therapeutics for successful clinical translation. Here, we provide a detailed analysis of the multifunctional carriers designed for different types of payloads, surveying the biomaterials used to construct the functional carriers. We then provide effective nucleic acid combinations employed to obtain more comprehensive outcomes, highlighting the critical factors involved in successful therapy. We conclude with an authors' perspective on the future of combinational therapy using nucleic acid therapeutics, articulating the main challenges to advance this promising approach to the clinical realm.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28450205     DOI: 10.1016/j.jconrel.2017.04.029

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  2 in total

1.  Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response.

Authors:  Armin Mahmoud Salehi Kheshti; Farnaz Hajizadeh; Asal Barshidi; Bentolhoda Rashidi; Farbod Ebrahimi; Simin Bahmanpour; Vahid Karpisheh; Fatemeh Karimian Noukabadi; Fariba Karoon Kiani; Hadi Hassannia; Fatemeh Atyabi; Seyed Hossein Kiaie; Fatah Kashanchi; Jamshid Gholizadeh Navashenaq; Hamed Mohammadi; Rafieh Bagherifar; Reza Jafari; Naime Majidi Zolbanin; Farhad Jadidi-Niaragh
Journal:  Pharm Res       Date:  2022-02-15       Impact factor: 4.200

2.  Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.

Authors:  Samarwadee Plianwong; Bindu Thapa; Remant Bahadur Kc; Cezary Kucharski; Theerasak Rojanarata; Hasan Uludağ
Journal:  Pharm Res       Date:  2020-02-03       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.